

MAR 31 2004 10:05 AM FR

TO 917033053230

P.03



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

LAD/DKT

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/763,011	Contreras	JAB-1415

Philip S Johnson
Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003

RECEIVED

MAR - 8 2004

J&J PAT. DKT. SECTION

INTERNATIONAL APPLICATION NO.
PCT/EP99/05991

I.A. FILING DATE	PRIORITY DATE
08/16/1999	08/14/1998

CONFIRMATION NO. 1386

371
ABANDONMENT/TERMINATION
LETTER


OC000000012017502

Date Mailed: 03/03/2004

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- * Applicant has failed to respond to the notification of MISSING REQUIREMENTS (Form PCT/DO/EO/905), mailed 04/26/2001 within the time period set therein.

Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.

INDIA L EVANS

Telephone: (703) 305-2936

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)

THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:

- Oath or Declaration
- Assignment
- Charge to Deposit Account 10-0750 *Authorization*
- Amendment
- Extension of Time
- Issue Fee Transmittal
- PCT Filing

- IDS-Form 1449

- MPEP 609/
- Notice of Appeal
- Brief
- Priority Document
- Status Inquiry
- Sequence Listings/Diskette
- Biological Deposit Declaration

Other *Associate Power of Attorney; Sequence listing and disk; Response to Notification of Defective Response; Petition for Revival of an Application for Patent Abandoned Unintentionally; Notification; Verification*

Serial No. 09/1763011 Docket No. JAB-1415 By: LAD
 Application of: Contreras et al Mailed: 7-29-03
 Enitled: *Drug Targets in Candida Albicans*


THE FOLLOWING HAS BEEN RECEIVED IN THE U.S. PATENT OFFICE ON THE DATE STAMPED HEREON:

- Oath or Declaration
- Assignment
- Charge to Deposit Account 10-0750 *Authorization*
- Amendment
- Extension of Time
- Issue Fee Transmittal
- PCT Filing

- IDS-Form 1449

- MPEP 609/
- Notice of Appeal
- Brief
- Priority Document
- Status Inquiry
- Sequence Listings/Diskette
- Biological Deposit Declaration

Other *Associate Power of Attorney; Sequence listing and disk; Response to Notification of Defective Response; Petition for Revival of an Application for Patent Abandoned Unintentionally; Notification; Verification*



DOCKET NO. JAB-1415

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Contreras et al.

Serial No.: 09/763,011 Art Unit: Unassigned

Filed : August 16, 1999 Examiner: Unassigned

For : DRUG TARGETS IN CANDIDA ALBICANS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner for Patents, Washington, D.C. 20231 on

7129103

(Date of Deposit)

Laura A. Donnelly

Name of applicant, assignee, or Registered Representative

Laura A. Donnelly

(Signature)

7129103

(Date of Signature)

AUTHORIZATION TO CHARGE DEPOSIT ACCOUNTCommissioner for Patents
Washington, D.C. 20231

Dear Sir:

Attached is a Petition for Revival of an Application for Patent Abandoned Unintentionally Under 37 CFR 1.137(b), Associate Power of Attorney, Response to Notification of Defective Response, and Verified Statement Under 37 CFR 1.821(f), for the above-captioned patent application.

Please charge Deposit Account No. 10-0750/JAB-1415/LAD in the name of Johnson & Johnson in the amount of \$24.00, representing the cost for claim fees in the above-captioned matter.

The Commissioner is hereby authorized to charge any additional fees which may be required to Account No. 10-0750/JAB-1415/LAD. This Authorization is being submitted in triplicate.

Respectfully submitted,

Laura A. Donnelly
Laura A. Donnelly
Attorney for Applicant(s)
Reg. No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729

Docket No. JAB-1415

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Contreras et al.
Serial No. : 09/763,011 Art Unit: Unassigned
Filed : LA. 08/16/99 Examiner: Unassigned
For : DRUG TARGETS IN CANDIDA ALBICANS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on

-7129113

(Date)

Laura A. Donnelly

Name of applicant, assignee, or Registered Representative

Laura A. Donnelly

(Signature)

-7129113

(Date of Signature)

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Dear Sir:

In response to the Notification of Defective Response, dated January 31, 2003, enclosed herewith is (1) a computer readable Sequence Listing and the required Verification Statement Under 37 C.F.R. 1.821(f) and (2) a fee sheet authorizing payment of the outstanding claim fee. As indicated in the Notification, although Applicants originally provided a computer readable Sequence Listing, the copy provided was "Damaged" and therefore unreadable. Applicants

MAR 31 2004 10:07 AM FR

TO 917033053230

P. 11

respectfully submit that all of the requirements set forth in the Notification have now been met.

A Petition for Revival pursuant to 37 C.F.R. §1.137(b) accompanies this request.

Respectfully Submitted,

Laura A. Donnelly
Laura A. Donnelly
Registration No. 38,435

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(732) 524-1729 (direct)
(732) 524-2134 (facsimile)

Dated: 3/31/04

Enclosures:

Computer Readable Sequence Listing
Verification Statement Under 37 C.F.R. 1.821(f)
Fee Sheet

MAR 31 2004 10:07 AM FR

TO 917033053230 P.13

Page 1 of 2



UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

U.S. INFORMATION

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20531
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/763,011	FEB 19 2001 Corderas	JAB-1415
TO FILE REFER TO:		INTERNATIONAL APPLICATION NO.
		PCT/EP99/05991
LA. FILING DATE		PRIORITY DATE
08/16/1999		08/14/1998
CONFIRMATION NO. 1386		
371 FORMALITIES LETTER		
OC00000009443735		

Date Mailed: 01/31/2003

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Diskette
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

Applicant's response filed 10/01/2001 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 04/26/2001 have not been completed.

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Additionally the following defects have been observed:

- Additional claim fees of \$24 as a non-small entity, including any required multiple dependent claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are due.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$24 for a Large Entity:

- Total additional claim fee(s) for this application is \$24
 - \$24 for 6 independent claims over 3.

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
 - APPLICANT MUST PROVIDE:
 - An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
 - For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

INDIA L EVANS

Telephone: (703) 305-2936

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/763,011	PCT/EP99/05991	JAB-1415

FORM PCT/DO/EO/916 (371 Formalities Notice)